CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer

CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer

Abstract Background The evasion of the immune response by tumor cells through programmed death-ligand 1 (PD-L1) has been identified as a factor contributing to resistance to radioimmunotherapy in lung cancer patients. However, the precise molecular mechanisms underlying the regulation of PD-L1 remai...

Full description

Bibliographic Details
Main Authors: Zixuan Li, Huichan Xue, Jinsong Li, Zhikun Zheng, Zhiwei Liu, Xiaorong Dong, Hongbo Wang, Jing Chen, Shuangbing Xu
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Radioimmunotherapy
Lung cancer
CDKL1
YBX1
PD-L1
Online Access:https://doi.org/10.1186/s13046-024-03007-w

Internet

https://doi.org/10.1186/s13046-024-03007-w

Similar Items